Aspire Biopharma Holdings, Inc.
A biopharmaceutical company developing a sublingual (under-the-tongue) drug delivery platform that lets medications and supplements absorb quickly into the bloodstream, skipping the stomach and liver. Founded in 2021, it came to life when the earlier shell company PowerUp Acquisition Corp. merged with it in early 2025 and the combined business took the name Aspire. The name "Aspire" nods to ambition, though the company has never spelled out a story behind it—a small mystery fans of naming lore can chew on.
Sold 4.32M
Bought 40.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| PowerUp Sponsor LLC10% owner · 2 transactions | — | 2.87Mas of Aug 2023 | — | — | 4.32M |
| Fell Donald G.Director · 4 transactions | — | 20.0Kas of Jun 2025 | — | 40.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -4.28M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.